U.S. Markets closed

Today’s Research Reports on Stocks to Watch: Daxor and Pfizer

NEW YORK, NY / ACCESSWIRE / October 31, 2018 / Pharmaceutical giant Pfizer was little changed on Tuesday despite mixed earnings and news about price increases on drugs from its CEO Ian Read. Shares of Daxor Corporation were exploding as the company announcing the publication of promising data.

RDI Initiates Coverage on:

Daxor Corporation

Pfizer Inc.

Daxor Corporation shares were up nearly 87% on Tuesday on about 5.3 million shares traded. The biotech company saw its shares gain after announcing the publication of encouraging new data in the Journal of the American College of Cardiology – Heart Failure. The new study cites 82% reduction in mortality and 56% reduction in rehospitalization 30 days after therapy guided by Daxor’s BVA-100 blood volume analyzer in acute heart failure patients. "This is a landmark study for Daxor as it provides peer review validation in a leading cardiology journal of the value of our technology and its potential to improve heart failure outcomes. Heart failure represents one of the largest areas of healthcare spending and one of the most significant treatment challenges for approximately 6 million US patients, which is expected to double as the population ages,” said Michael Feldschuh, CEO of Daxor. “The BVA-100 provides a simple, rapid, inexpensive, non-invasive, and most importantly, objective measurement of volume status and composition. This precision enables individualization of treatment and significantly better outcomes for patients.”

Access RDI’s Daxor Corporation Research Report at:

Pfizer Inc. shares were down 0.79% yesterday on roughly 33.6 million shares traded. The Company reported earnings that beat on bottom line but missed revenue estimates of the street. The pharmaceutical giant reported adjusted EPS of 78 cents on revenue of $13.3 billion. Street expected an EPS of 75 cents on revenue of $13.53 billion. The company's CEO Ian Read said on a company conference call that drug price increases will come this January. The pharmaceutical company had postponed drug price increases on its products that had been scheduled for July 1st after a tweet from President Trump about the company. Trump had tweeted on July 10th, "Just talked with Pfizer CEO and @SecAzar on our drug pricing blueprint. Pfizer is rolling back price hikes, so American patients don’t pay more. We applaud Pfizer for this decision and hope other companies do the same. Great news for the American people!" According to a FactSet transcript, Read said, “Look, I don’t think our pricing situation has changed. I have at this moment in time no different view about how we will take price increases as we did last year.” The company now expects its revenue to range between $53.0 billion to $53.7 billion as compared to the earlier range of $53.0 - $55.0 billion. Adjusted EPS outlook has also been narrowed to $2.98 to $3.02 from $2.95 to $3.05.

Access RDI’s Pfizer Inc. Research Report at:

Our Actionable Research on Daxor Corporation (NYSE: DXR ) and Pfizer Inc. (NYSE: PFE) can be downloaded free of charge at Research Driven Investing.

Research Driven Investing

We are committed to providing relevant and actionable information for the self-directed investor. Our research is reputed for being a leader in trusted, in-depth analysis vital for informed strategic trading decisions. The nimble investor can leverage our analysis and collective expertise to execute a disciplined approach to stock selection.

RDInvesting has not been compensated; directly or indirectly; for producing or publishing this document.

Disclaimer: This article is written by an independent contributor of RDInvesting.com and Nadia Noorani, a CFA® charter holder, has provided necessary guidance in preparing the document templates. RDInvesting.com is neither a registered broker dealer nor a registered investment advisor. For more information please read our full disclaimer at www.rdinvesting.com/disclaimer.


For any questions, inquiries, or comments reach out to us directly at:



CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: RDInvesting.com